← All organizations

Eyevance

For profitContributed to NMEWebsite ↗

Also known as: EYEVANCE | Eyevance Pharmaceuticals

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 2

First clinical trial

Last known activity

Oct 31, 2019

Acquired by Santen Inc. on Dec 19, 2021

Timeline

1980s

Jul 21, 1989
tobramycin— Marketing Organization

1990s

Dec 30, 1994
rimexolone— NDA Secondary Org
Dec 30, 1994
rimexolone— NDA Organization

2010s

Jun 1, 2017
Eyevance— Founded

2020s

Dec 19, 2021
Santen Inc.— Acquired By

Drugs by trial phase (1 distinct, 1 trials)

Phase 2 (1 own, 0 via acquisition)

nexagon

Indications

Approved for

Marketed drugs (8)

Recent trials (1)

NCT04081103CollaboratorPhase 2Oct 31, 2019

Details

Founded: Fort Worth, TX, US Jun 1, 2017
Last known activity: Oct 31, 2019

Designations held

Priority review